Pristiq (Desvenlafaxine) Tapering Guide

Pristiq (desvenlafaxine) is an SNRI antidepressant — the active metabolite of venlafaxine — marketed as Pristiq. It is used for major depression. This guide and medication taper calculator help you plan how to come off desvenlafaxine safely with your prescriber.

Dosage

Desvenlafaxine is supplied as extended-release tablets (commonly 25 mg and 50 mg) that must not be split, crushed, or chewed. There is no licensed liquid in most markets, so small steps usually require a compounded preparation or a carefully supervised cross-taper to venlafaxine.

Short half-life and very high withdrawal-severity ratings mean gradual hyperbolic tapering — not abrupt stops — when you want to get off antidepressants.

Desvenlafaxine taper schedule

Choose a common starting dose to preview an example hyperbolic schedule you can take to your prescriber — free, no email required. This example has 26 steps and takes about 100 weeks in total. It is a planning tool, not a dose instruction.

Starting dose

Selected start: 50 mg/day · 1× daily
Taper speed: Slow
Region (formulations): US
Modelled occupancy at start: ~70.8%

Tablet/liquid products used for dosing tips — not your location. Example uses US formulary; change region in the custom builder.

Limited / derived PET anchor — curve is indicative

Swipe sideways to see every column.

Step	Daily (mg)	How to take it	Per dose × 1/day	Hold (weeks)
0	50	Your current dose — hold steady before step 1.	50 mg × 1	—
1	44.26	GPSee liquid / compounding note below	44.26 mg × 1	4
2	39.51	GPSee liquid / compounding note below	39.51 mg × 1	4
3	25	Take 1 × 25 mg Pristiq tablet (25 mg active ingredient total).	25 mg × 1	4
4	22.95	GPSee liquid / compounding note below	22.95 mg × 1	4
5	21.15	GPSee liquid / compounding note below	21.15 mg × 1	4
6	19.55	GPSee liquid / compounding note below	19.55 mg × 1	4
7	18.1	GPSee liquid / compounding note below	18.1 mg × 1	4
8	16.75	GPSee liquid / compounding note below	16.75 mg × 1	4
9	15.55	GPSee liquid / compounding note below	15.55 mg × 1	4
10	14.45	GPSee liquid / compounding note below	14.45 mg × 1	4
11	13.45	GPSee liquid / compounding note below	13.45 mg × 1	4
12	12.5	GPSee liquid / compounding note below	12.5 mg × 1	4
13	11.65	GPSee liquid / compounding note below	11.65 mg × 1	4
14	10.85	GPSee liquid / compounding note below	10.85 mg × 1	4
15	10.1	GPSee liquid / compounding note below	10.1 mg × 1	4
16	9.4	GPSee liquid / compounding note below	9.4 mg × 1	4
17	8.75	GPSee liquid / compounding note below	8.75 mg × 1	4
18	8.15	GPSee liquid / compounding note below	8.15 mg × 1	4
19	7.6	GPSee liquid / compounding note below	7.6 mg × 1	4
20	7.05	GPSee liquid / compounding note below	7.05 mg × 1	4
21	6.55	GPSee liquid / compounding note below	6.55 mg × 1	4
22	6.1	GPSee liquid / compounding note below	6.1 mg × 1	4
23	5.65	GPSee liquid / compounding note below	5.65 mg × 1	4
24	5.25	GPSee liquid / compounding note below	5.25 mg × 1	4
25	5	GPSee liquid / compounding note below	5 mg × 1	4

Rows highlighted: larger occupancy drop than target — consider smaller steps or longer holds. If symptoms are intolerable, return to the previous dose and talk to your prescriber.

Steps that cannot be made from whole or half licensed tablets point to the liquid / compounding note below — ask your prescriber before changing how you take your dose.

Want a copy to keep?

The full desvenlafaxine schedule is already shown below. Enter your email to also receive a PDF and HTML copy you can save or share with your prescriber — optional, and we never gate the schedule behind it.

It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.

Dose vs occupancy

This example is spread across 26 gradual steps. The curve below shows why the last few milligrams matter most: at low doses, small dose changes produce large drops in serotonin-transporter occupancy.

What this shows: the non-linear relationship between dose and serotonin transporter (SERT) occupancy. The curve is flat at high doses — most transporters are already blocked, so a dose cut has little biological impact — and much steeper at low doses, where even a 1–2 mg reduction causes a disproportionately large drop in occupancy. Your taper steps are spaced along this curve so each step removes a similar amount of occupancy.

Modelled Hill-curve occupancy — illustrative only. PET-derived parameters vary by study; your prescriber may use different clinical targets. Small mg changes near zero can still produce large occupancy shifts.

Want a full taper protocol?

This page shows a quick schedule for this drug. For the guided path — pre-taper risk quiz, formulation-aware steps, and email delivery — continue in the builder.

Start taper protocol →

How to Taper Off Pristiq (Desvenlafaxine) Safely

How to taper off Pristiq (desvenlafaxine) safely starts with the tablet: extended-release tablets must not be split, crushed, or chewed, and there is no licensed liquid in most markets. A hyperbolic reduction still applies — the question is how the small steps will actually be made.

Desvenlafaxine is an SNRI — the active metabolite of venlafaxine — used for major depression. It is marketed as Pristiq. The calculator on this page drafts an example schedule — it is not a dose instruction.

About this guide

This is general information about desvenlafaxine for people taking it, thinking about starting or stopping. It is not personal medical advice, and it does not tell you what dose to take or how to change one. Those decisions belong with the prescriber who knows your history.

If anything here differs from what your own doctor or pharmacist has told you, go with them.

How long people usually take it

Desvenlafaxine is not usually a short course. NICE advises that people starting an antidepressant should be told treatment may need to continue for at least six months after symptoms have settled, with regular review. For people who have had several episodes, or who are at higher risk of becoming unwell again, it is often considerably longer.

This matters if you are thinking about stopping, because stopping early carries a real risk. In a UK trial in general practice, among people who had been well enough that stopping seemed reasonable, 56% of those who stopped became unwell again within a year, compared with 39% of those who continued. That is not an argument for staying on antidepressants indefinitely, and many people come off them successfully and stay well. It is an argument for the timing being a decision you make deliberately with your prescriber, rather than one you make on the day you run out.

What people commonly notice while taking it

People commonly notice nausea, dry mouth, sweating, dizziness, insomnia, and sexual side effects. As with other SNRIs, blood pressure can rise and is worth checking.

The extended-release tablet is meant to be swallowed whole. Splitting it dumps the dose.

Thinking about stopping

There are many different reasons for people to think about stopping. This can be that they have been well for a long time, the side effects have come to outweigh the benefit, they are planning a pregnancy, or circumstances have changed.

What helps is having the conversation before the plan rather than after it. Some questions that are worth taking to the appointment:

how long you have been taking it, and how long it has been since you last felt unwell
whether anything in the next few months makes this a difficult time to start
what happened if you have tried before, and what you would do differently
how the two of you will tell withdrawal symptoms from the original problem returning
who you contact, and how quickly, if it becomes difficult

One thing is worth being clear about: desvenlafaxine should not be stopped abruptly. NICE advises against stopping antidepressants suddenly except in rare and serious circumstances, such as a severe reaction to the medicine.

What coming off Pristiq actually feels like, week by week

Desvenlafaxine’s half-life is about 11 hours. When a reduction is larger than someone can comfortably absorb — including the common jump between listed tablet strengths — dizziness, brain zaps, nausea, and agitation can appear within a day or two. Withdrawal-severity ratings for this drug are high.

How common is this? The research does not give a clean answer, and it is worth being straight about that. A large review published in 2024 found that about a third of people had at least one symptom after stopping an antidepressant, but also that about one in six had symptoms after stopping a dummy tablet, leaving roughly one in six or seven that could be attributed to the medicine itself. A reanalysis published in 2025, which looked only at the studies that asked people systematically rather than waiting for them to volunteer symptoms, arrived at around half.

Almost all of that research involves people who had taken antidepressants for a few months. Very little of it describes what happens after several years, which is the situation many people reading this are actually in.

Those figures are for antidepressants as a group. Desvenlafaxine sits toward the difficult end, in part because the tablet leaves so few intermediate options.

Withdrawal or relapse — how to tell them apart

Withdrawal symptoms tend to begin within a day or two of a change, are often physical and sensory, and may settle if the previous dose is restored.

A return of depression or anxiety tends to build over weeks, resembles how your original illness felt rather than a physical upset, and does not lift within a day or two if the dose goes back up.

That distinction is useful, but it is not perfect and it should not be used as a test you apply alone. NICE's guidance on withdrawal makes the point directly that withdrawal symptoms can be delayed, can be prolonged, and can affect mental health as well as physical health. If you cannot tell which you are dealing with, that is a normal position to be in and a good reason to speak to your prescriber.

Why the last part is often the hardest

This catches people out, and it is worth understanding, because it is the most common reason a reduction that had been going well stops going well.

The relationship between the dose and the effect at the nerve cell is not a straight line. At higher doses the effect is close to its ceiling, so removing some milligrams changes relatively little. At low doses, removing the same number of milligrams makes a much bigger difference.

In practical terms, a reduction that you barely noticed near the top can feel like a much larger change near the bottom, even though the arithmetic looks identical. This is why NICE recommends reductions that are proportionate to the dose you are currently taking, so that the steps become smaller as the dose comes down, and it is why the final stretch often takes longer than everything before it.

It is a feature of how the medicine works. It is not a sign that something has gone wrong, and it is not a sign that you are doing it badly.

Listed tablets commonly stop at 25 mg. That is a long way from nothing on a hyperbolic curve. Compounded liquid, or a carefully supervised change to a more flexible venlafaxine form, is how some finishing plans are made — neither is something to attempt from a webpage.

Pristiq taper schedules by starting dose (100, 50, 25 mg)

How to taper off desvenlafaxine is shaped by tablets that will not divide. The table above is an example occupancy-based plan to take to your prescriber, not a sequence to run at home.

Extended-release tablets commonly come in 25 mg and 50 mg (higher strengths exist in some markets). Going from one listed strength to the next is a linear cut. Small steps usually require a compounded preparation or another approach your prescriber discusses with you.

Preview a planning schedule →

If it gets worse: pausing and reinstatement

If a reduction is harder than you expected, speak to your prescriber. Sort the formulation out before inventing the next milligram cut — the tablet will not do the last stretch on its own.

This is educational information. Do not change your dose without your prescriber's input.

The forms desvenlafaxine comes in

Desvenlafaxine is supplied as extended-release tablets that must not be split, crushed, or chewed. There is no licensed liquid in most markets.

Small steps usually require a compounded preparation or a carefully supervised cross-taper to venlafaxine, which has more flexible options. Whether that applies to you is a question for your prescriber.

A note on what your leaflet says

The patient information leaflet in the box often says that when stopping, the dose should be reduced over a period of at least one to two weeks. NICE's guidance on withdrawal describes a slower, stepwise reduction that gets gentler as the dose falls, and says the process can take several months or more.

If your leaflet and your prescriber appear to disagree, this is usually why. Neither is making a mistake. The leaflet states a minimum; the guideline describes what many people actually need.

When to get help quickly

Contact your prescriber promptly if:

your mood drops significantly, or you feel worse than you did before you started
you have thoughts of harming yourself or ending your life. If you are in immediate danger, call emergency services — 911 in the US, or your local emergency number
symptoms after a dose change are getting worse rather than settling, or you cannot manage them
you become confused or unsteady, or feel physically unwell in a way that is new
you develop agitation with shivering, twitching, a racing heart or a fever
you become pregnant, or are planning to

Stopping desvenlafaxine suddenly is not the answer to any of the above. Speak to someone first. Crisis lines for your region are listed at the bottom of this page.

The bottom line

Coming off desvenlafaxine is doable when the formulation problem is solved before the last stretch. Take the planning table to your prescriber, and ask how doses below a tablet will be made.

Milligram scale guidance (advanced — prescriber/pharmacist approval required)

When a dose is below what you can split from a licensed tablet, some people weigh crushed tablet powder. This is not exact chemistry — it is a last resort. Liquid or compounded formulations are safer when available.

Resolution: at least 0.001 g (1 mg) — not a kitchen scale.
Include a calibration weight and use a draft shield if possible.
Weigh on a stable surface; tare your container first.
Crushed tablet weight ≠ exact active ingredient — drug may not be evenly distributed; prefer liquid or compounded specials when available.
Never split enteric-coated (EC) or extended-release (XR) products — discuss with your pharmacist.

Example searches (confirm specs before buying):

Key facts about hyperbolic antidepressant tapering

The calculator algorithm is based on peer-reviewed research and has been reviewed by our medical advisors to ensure the accuracy of the tapering model.

72%
discontinued their antidepressant using hyperbolic tapering strips in a real-world study
71% of the same people had previously tried to stop at least once and been unsuccessful; the study did not record which method those earlier attempts used. Figures come from tapering-strip research and may not generalise to every taper.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
56 days
median taper length in that tapering-strip study — not a target; many people taper over 6–12 months or longer
This median reflects tapering-strip use in one study. Your timeline depends on how long you have taken the medication, your withdrawal symptoms, and previous attempts — slower is often safer.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
10%
serotonin transporter occupancy per tapering step
This linear reduction prevents withdrawal. Slower, more gradual tapering over several months has shown greater success in reducing withdrawal symptoms than short tapers.
Source: Horowitz et al., The Lancet Psychiatry 2019

Claro — tapering companion

A protocol isn’t enough — you need support.

Tapering can take months, sometimes years. Claro helps you track each step, log symptoms, and spot when a reduction was too fast — with psychiatrist-reviewed guidance. Join early access while we launch the app.

Why an AI companion for tapering? →

Other medications with similar pharmacology or a higher population withdrawal-risk profile. Each guide links to a pre-filled hyperbolic schedule for that drug.

Other SNRI guides

Pre-taper risk quiz Symptom checker Ask a psychiatrist Find help

Frequently asked questions about desvenlafaxine

Common questions about how to taper off desvenlafaxine, hyperbolic schedules, and withdrawal — written for people who want to come off antidepressants safely with their prescriber.

How do you taper off Pristiq (desvenlafaxine)?

Pristiq tablets are extended-release and cannot be split, so tapering below the 25 mg tablet needs either a compounded liquid or a prescriber-led switch to venlafaxine, which has more flexible formulations. Reduce hyperbolically in small, even steps and hold each for 2-4 weeks, because desvenlafaxine has a short half-life and a very high withdrawal-severity rating.

Why can’t you split Pristiq tablets to taper?

Pristiq uses an osmotic extended-release shell that releases the drug slowly; splitting or crushing it destroys that mechanism and releases the dose all at once — you may even see the empty shell in your stool. To make the small doses a taper needs, use a compounded desvenlafaxine liquid or cross over to venlafaxine under your prescriber’s supervision.

Can you stop Pristiq cold turkey?

No — stopping Pristiq cold turkey is strongly discouraged. Desvenlafaxine has a short half-life (~11 hours) and a very high withdrawal-severity rating, so abrupt discontinuation commonly triggers brain zaps, dizziness and nausea within a day. If you have already stopped and feel unwell, contact your prescriber about reinstating and then tapering gradually.

What is an antidepressant tapering calculator?

An antidepressant tapering calculator is a free online medication taper calculator that turns a current dose into an example step-by-step reduction you can review with a prescriber. The Claro calculator uses the hyperbolic method: each step removes a similar percentage of receptor occupancy rather than the same number of milligrams. Take that draft to your clinician when you decide to wean off antidepressants — it is a planning tool, not a dose instruction.

Why use a tapering calculator?

A medication taper calculator turns receptor-occupancy research into a concrete hyperbolic taper schedule you can read in minutes. It is especially useful when you want to come off antidepressants gradually, because the last few milligrams cause the largest change in modelled occupancy. Use it to preview example steps and talk through liquid or split-tablet options when you wean off antidepressants with your prescriber.

How does an antidepressant taper calculator work?

The calculator models how much of your serotonin (or noradrenaline) transporter is occupied at each dose using a Hill-equation curve fitted to published PET studies. It then chooses dose reductions so that each step removes a roughly equal amount of occupancy — the hyperbolic method described by Horowitz and Taylor (2019). The schedule is then rounded to doses you can actually achieve with available tablets, capsules, or liquids in your region.

What is hyperbolic tapering and why is it recommended?

Hyperbolic tapering means reducing your dose by smaller and smaller milligram amounts as you get lower, so the change in receptor occupancy at each step stays about the same. It is recommended because antidepressants follow a hyperbolic dose-response curve: at low doses, small milligram changes have outsized effects. Hyperbolic tapering is endorsed in the Maudsley Deprescribing Guidelines (2024), the UK NICE NG222 guideline, and the Dutch multidisciplinary deprescribing document.

What is the safest way to taper off antidepressants?

The safest way is gradual, supervised, and individualised. Work with a prescriber, hold each dose for at least 2-4 weeks before reducing again, and use liquid or compounded formulations once tablets cannot be split small enough. If symptoms become severe, return to the previous stable dose, allow time to settle, then resume with smaller steps. This calculator is educational; do not change medication without clinical supervision.

How slowly should antidepressants be reduced?

Most people benefit from reductions of around 5-10% of the previous dose every 2-4 weeks, and even more slowly toward the end of the taper. Higher-risk drugs — paroxetine, venlafaxine, and duloxetine — typically need slower steps and longer holds. There is no fixed timeline: many people take 6-12 months to fully get off antidepressants and some take longer, especially after years of treatment.

What are common antidepressant withdrawal symptoms?

The most commonly reported antidepressant withdrawal symptoms include dizziness, "brain zaps" (brief electric-shock sensations), nausea, fatigue, insomnia, vivid dreams, headaches, irritability, anxiety, and mood swings. A 2024 Lancet Psychiatry meta-analysis (Henssler et al.) estimated discontinuation symptoms in around 31% of people, with about 2.8% experiencing severe symptoms. Earlier work (Davies & Read, 2019) reported higher rates of 56% across surveyed populations.

What is the difference between antidepressant withdrawal and relapse?

Withdrawal usually starts within days of a dose reduction, includes physical symptoms like dizziness or brain zaps, and improves when you reinstate the previous dose. Relapse of the original condition typically appears weeks later, is dominated by your original symptoms, and is not relieved within hours by reinstating. The Cosci & Chouinard (2020) framework is the standard taxonomy clinicians use to tell the two apart.

Is it dangerous to stop antidepressants cold turkey?

Stopping antidepressants cold turkey is widely discouraged. Sudden discontinuation increases the risk of severe withdrawal symptoms, including dizziness, brain zaps, and emotional changes, and can trigger reinstatement. Short half-life drugs such as paroxetine and venlafaxine carry the highest risk. If you have already stopped abruptly and feel unwell, contact your prescriber; reinstating the previous dose and then tapering more gradually is the standard recommendation.

Why are the last antidepressant dose reductions often the hardest?

Because the dose-occupancy curve is hyperbolic. At low doses, a 1-2 mg change can produce as much receptor change as a 10-20 mg change at higher doses. This is why people often feel fine for most of the taper and then struggle at the end. A medication taper calculator addresses this by making the final steps in tenths of a milligram, which usually requires a liquid formulation or compounded preparation.

Which antidepressants are hardest to taper off?

Paroxetine (Paxil/Seroxat) and venlafaxine (Effexor) are most often reported as the hardest antidepressants to come off, followed by duloxetine (Cymbalta). They share short half-lives and steep dose-occupancy curves, so missed doses or sharp reductions can trigger withdrawal symptoms within days. Fluoxetine (Prozac), with its very long half-life, is generally the easiest and is sometimes used as a "bridge" when switching off shorter-acting drugs.

Need a different dose or speed?

Use the guided builder to enter your current dose, region, and taper preset — then email a draft you can review with your prescriber.

Request custom protocol →

Clinical references

[1]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019.doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
[2]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024.doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
[3]Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors 2019.doi:10.1016/j.addbeh.2018.08.027Systematic review: 56% of people who discontinue antidepressants experience withdrawal effects; 46% rate them as severe.
[4]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024.doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
[5]Groot PC, van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321103932772% of patients successfully discontinued antidepressants after switching to the hyperbolic model; 71% had previously failed to come off without tapering strips.
[6]Groot PC, van Os J. Antidepressant tapering strips to help people come off medication: real-world outcomes. Therapeutic Advances in Psychopharmacology 2023.doi:10.1177/20451253231171518Of 1,194 patients using hyperbolic taper strips after previous failed attempts, ~71% successfully discontinued their antidepressant.
[7]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
[8]Hengartner MP et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320967183Descriptive analysis of 69 protracted withdrawal cases: median duration 79 weeks; 47% report suicidality during withdrawal.
[9]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020.doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
[10]Kalfas M et al. Incidence and Nature of Antidepressant Discontinuation Symptoms. JAMA Psychiatry 2025.doi:10.1001/jamapsychiatry.2025.1362Recent meta-analysis: dizziness was the most common discontinuation symptom in the first 2 weeks after stopping antidepressants, followed by nausea, vertigo, and nervousness.
[11]Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Canadian Medical Association Journal 2017.doi:10.1503/cmaj.160991Clinical review of antidepressant discontinuation syndrome: onset within days of dose reduction, typical symptom course, and management.
[12]Papp A, Onton J. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders 2018.doi:10.4088/pcc.18m02311Characterises "brain zaps" — brief electric-shock sensations — as a common antidepressant discontinuation symptom.
[13]Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Therapeutic Advances in Psychopharmacology 2025.doi:10.1177/20451253251404780Systematic review of acute and persistent antidepressant withdrawal syndromes; reinforces reducing only when stable and under supervision.
[14]Horowitz M, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022.doi:10.1192/bja.2021.62Frames how clinicians can distinguish antidepressant withdrawal from relapse of the underlying condition.
[15]Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2021.doi:10.1038/s41380-021-01285-wSystematic review of dose–SERT-occupancy relationships across antidepressants; confirms the hyperbolic curve underlying proportional tapering.
[16]Reeve R, Turner JR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Journal of Biopharmaceutical Statistics 2013.doi:10.1080/10543406.2012.756496Explains how the Hill equation, Michaelis-Menten, and logistic models relate — the mathematical basis for the occupancy curve used here.
[17]Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice 2012.LinkShows how SERT occupancy explains the non-linear dose–response curves of SSRIs.
[18]Cohrs D, Shapiro B. The relationship between SERT occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering SRI antidepressants. SSRN (preprint) 2026.doi:10.2139/ssrn.6176553Argues the SERT-occupancy to serotonin relationship is itself hyperbolic, reinforcing proportional (hyperbolic) tapering.
[19]Moncrieff J et al. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological Medicine 2025.doi:10.1017/S0033291725100652Reappraisal of recent withdrawal-incidence evidence; relevant to how withdrawal rates are interpreted.
[20]Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology 2015.doi:10.1177/2045125315612334Practical review of how to manage antidepressant discontinuation symptoms, including tapering and reinstatement.
[21]Groot PC, van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320954609Long-term follow-up (1–5 years) of patients who discontinued antidepressants using hyperbolic taper strips.
[22]Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. L'Encéphale 1999.LinkHalf-life data for SSRIs — explains why short-half-life drugs (paroxetine, venlafaxine) provoke faster withdrawal.
[23]Mayo Clinic. Antidepressant withdrawal: Is there such a thing?. Mayo Clinic — Expert Answers 2024.LinkPatient-facing explainer on antidepressant discontinuation symptoms and gradual tapering.
[24]NHS Scotland — Right Decision Service. Antidepressants — quality prescribing: difficulty withdrawing from an SSRI/SNRI. NHS Scotland 2024.LinkNHS Scotland guidance on recognising and managing difficulty withdrawing from SSRIs/SNRIs.
[25]The Carlat Psychiatry Report. Clinical pearls for hyperbolic tapering of psychiatric medications in older adults. The Carlat Report 2024.LinkPractical clinical pearls for applying hyperbolic tapering, including in older adults.
[26]Royal College of Psychiatrists. Stopping antidepressants — information for patients and carers. Royal College of Psychiatrists 2024.LinkRCPsych patient-facing guidance on coming off antidepressants safely.
[27]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022.LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
[28]National Institute for Health and Care Excellence (NICE). Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. NICE guideline [NG215]. NICE 2022.LinkUK national guideline on withdrawal: symptoms can be delayed or prolonged, and reductions should get gentler as the dose falls.
[29]Lewis G et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine 2021.doi:10.1056/NEJMoa2106356Among people well enough that stopping seemed reasonable, 56% who stopped became unwell again within a year versus 39% who continued.
[30]Royal College of Psychiatrists. Stopping antidepressants — position statement (CR225). Royal College of Psychiatrists 2020.LinkRCPsych acknowledges withdrawal can be severe and long-lasting; recommends slow, individualised tapers.
[31]NHG et al. Multidisciplinary document: Discontinuation of SSRIs and SNRIs (2018; revised 2023). Multidisciplinary Document (Netherlands) 2018.LinkFirst national guideline to explicitly endorse hyperbolic tapering and the use of taper strips (compounded by Regenboog Apotheek).
[32]Medicines and Healthcare products Regulatory Agency (MHRA). Summary of Product Characteristics — SSRI and SNRI products (UK). electronic Medicines Compendium (emc) 2023.LinkAuthoritative UK formulary data (tablet strengths, oral solutions) used to validate the UK region in the calculator.
[33]U.S. Food and Drug Administration. Prescribing information (Structured Product Labeling) for SSRI/SNRI products. FDA / DailyMed 2024.LinkAuthoritative US formulary data (tablet strengths, oral solutions/concentrates) used to validate the US region in the calculator.
[34]Health Canada. Health Canada — Drug Product Database. Health Canada 2024.LinkAuthoritative Canadian formulary data used to validate the Canada region in the calculator.
[35]Therapeutic Goods Administration (TGA). Therapeutic Goods Administration — Australian Register of Therapeutic Goods (ARTG). TGA / ARTG 2024.LinkAuthoritative Australian formulary data used to validate the Australia region in the calculator.
[36]College ter Beoordeling van Geneesmiddelen (CBG-MEB). CBG-MEB — Medicines Information Bank (Netherlands). CBG-MEB 2024.LinkAuthoritative Dutch formulary data; cross-checked with Regenboog Apotheek taper-strip availability.
[37]Regenboog Apotheek, Cinetto. Taperingstrip.com — Regenboog Apotheek. Patient resource (NL) 2024.LinkPioneer of standardised taper strips referenced in the Dutch national guideline.

If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →